Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sage Therapeutic Com (NQ: SAGE ) 6.050 -0.030 (-0.49%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sage Therapeutic Com < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom December 08, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... Via Benzinga Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress December 08, 2021 From Sage Therapeutics, Inc. Via Business Wire 5 Value Stocks To Watch In The Healthcare Sector December 06, 2021 What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... Via Benzinga Earnings Scheduled For November 2, 2021 November 02, 2021 Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... Via Benzinga Analyst Ratings For Sage Therapeutics October 12, 2021 Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings... Via Benzinga Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients December 01, 2021 Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone... Via Benzinga The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case December 01, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD December 01, 2021 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Host Sage FutureCast Webcast November 29, 2021 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference November 24, 2021 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference November 11, 2021 From Sage Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Friday's After-Market Session November 08, 2021 Gainers Kiromic BioPharma (NASDAQ:KRBP) ... Via Benzinga What 8 Analyst Ratings Have To Say About Sage Therapeutics November 03, 2021 Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings ... Via Benzinga 10 Biggest Price Target Changes For Wednesday November 03, 2021 Needham boosted Paycom Software, Inc. (NYSE:PAYC) ... Via Benzinga Sage Therapeutics Inc (SAGE) Q3 2021 Earnings Call Transcript November 02, 2021 SAGE earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed November 02, 2021 Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a... Via Benzinga Artificial Intelligence Could Be About To Replace Your Doctor November 02, 2021 FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And... Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US November 02, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... Via Benzinga Exposures COVID-19 Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress November 02, 2021 From Sage Therapeutics, Inc. Via Business Wire Preview: Sage Therapeutics's Earnings November 01, 2021 Sage Therapeutics (NASDAQ:SAGE) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts... Via Benzinga The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline October 31, 2021 Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... Via Benzinga Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention October 27, 2021 Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... Via FinancialNewsMedia Exposures Product Safety B. Riley Sees 'Significant Potential' In This Beaten-Up Biotech Stock October 21, 2021 B. Riley analyst calls Seelos Therapeutics Inc (NASDAQ: Via Benzinga Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 October 20, 2021 From Sage Therapeutics, Inc. Via Business Wire What 7 Analyst Ratings Have To Say About Sage Therapeutics October 20, 2021 Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings... Via Benzinga Abbot Labs and Biogen Outshine Novavax in the Health Care Sector October 20, 2021 Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company... Via Benzinga 10 Biggest Price Target Changes For Wednesday October 20, 2021 Mizuho cut QUALCOMM Incorporated (NASDAQ: QCOM) price target from $180 to $165. QUALCOMM shares fell 0.3% to $132.13 in pre-market trading. Deutsche Bank raised the price... Via Benzinga Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022 October 19, 2021 From Sage Therapeutics, Inc. Via Business Wire A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector October 18, 2021 FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the... Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Rising Oil Prices and Yields Makes Market Navigation More Complex October 05, 2021 Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise... Via Benzinga Exposures Fossil Fuels < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
